Tarpeyo is owned by Calliditas.
Tarpeyo contains Budesonide.
Tarpeyo has a total of 1 drug patent out of which 0 drug patents have expired.
Tarpeyo was authorised for market use on 15 December, 2021.
Tarpeyo is available in capsule, delayed release;oral dosage forms.
Tarpeyo can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.
The generics of Tarpeyo are possible to be released after 07 May, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8491932||CALLIDITAS||Compositions for the oral delivery of corticosteroids|| |
(6 years from now)
|New Product (NP)||Dec 15, 2024|
Market Authorisation Date: 15 December, 2021
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic